AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: patient

California Senate Committee Advances Bill to Expose Patients to Doctor Substance Abuse, Says Consumer watchdog

SACRAMENTO, Calif., July 7, 2025 /PRNewswire/ -- Despite pleas from families throughout California, who have voiced their concerns about exposing patients to substance-abusing doctors,...

Leading Medical Professional Societies, Patient Sue HHS, Robert F. Kennedy, Jr., for Unilateral Vaccine Changes

AAP, ACP, APHA, IDSA, MPHA, and SMFM Join Together to Stop Assault on Public Health BOSTON, July 7, 2025 /PRNewswire/ -- Today, the American Academy...

Aerolib Healthcare Solutions Unveils Aerolib AI: The Ultimate Appeals Machine

Aerolib AI Revolutionizes Hospital Revenue Recovery with Breakthrough Appeals and Denials Platform
Aerolib AI Revolutionizes Hospital Revenue Recovery with Breakthrough Appeals and Denials Platform

Better by MTA Highlights Platinum Members Elevating Global Healthcare Standards

PALM BEACH GARDENS, Fla., July 7, 2025 /PRNewswire/ -- Better by MTA, the leading medical tourism platform, is proud to spotlight its distinguished Platinum Members—organizations...

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Validation Data on 60 Patients published in Cancer Genetics CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...

Simplex Quantum Welcomes Dr. Marco Perez as an Advisor to Advance AI-Driven Heart Failure Detection

TOKYO, July 7, 2025 /PRNewswire/ -- Simplex Quantum, an AI-driven healthcare technology company, is proud to announce that Dr. Marco Perez, Associate Professor of...

MY DR NOW Opens Tucson Clinic, Ushering in a New Era of Convenient Care for Southern Arizona

TUCSON, Ariz., July 7, 2025 /PRNewswire/ -- Southern Arizona is getting another dose of hassle-free healthcare as MY DR NOW opens its next clinic...

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients...

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/...

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

One of the largest multi-region healthcare systems in the US expands enterprise imaging cloud service from Sectra with pathology to leverage integrated diagnostics in...

LINKÖPING, Sweden and SHELTON, Conn., July 7, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) module for digital pathology will...

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges HIMS Investors with Losses to Contact the Firm

RADNOR, Pa., July 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient